Fellow of The Academy of Medical Sciences, United Kingdom
Her primary areas of investigation include Immunology, Virology, Tuberculosis, Tuberculosis vaccines and Mycobacterium tuberculosis. Her research in Vaccination, BCG vaccine, Antigen, Immunogenicity and Immune system are components of Immunology. Her studies deal with areas such as Vaccinia and ELISPOT as well as Virology.
Her research integrates issues of Heterologous, Disease and Immunity in her study of Tuberculosis. The Tuberculosis vaccines study combines topics in areas such as Internal medicine, Clinical trial and Vaccine evaluation. Helen McShane interconnects CD8 and Interferon gamma in the investigation of issues within Mycobacterium tuberculosis.
Helen McShane focuses on Immunology, Tuberculosis, Vaccination, Tuberculosis vaccines and Virology. Her Immunology study frequently draws connections between related disciplines such as Mycobacterium tuberculosis. Her work investigates the relationship between Tuberculosis and topics such as Clinical trial that intersect with problems in Pediatrics.
Her study in Vaccination is interdisciplinary in nature, drawing from both Regimen, Randomized controlled trial, Immunization, Immunity and Modified vaccinia Ankara. Her studies in Tuberculosis vaccines integrate themes in fields like Global health, Viral Vaccine and Adverse effect. Her biological study spans a wide range of topics, including Heterologous, Vaccinia, Mycobacterium bovis and Viral vector.
Tuberculosis, Immunology, Vaccination, Mycobacterium tuberculosis and Immune system are her primary areas of study. Her Tuberculosis research integrates issues from Clinical trial, T cell, CD8, Intensive care medicine and Nasal administration. Helen McShane studies Immunology, namely Vaccine efficacy.
Her Vaccination study combines topics from a wide range of disciplines, such as Cellular immunity, Family medicine, Lung, Antigen presentation and Parenchyma. Her research in Mycobacterium tuberculosis intersects with topics in Pathogen, Virology, Immunogenicity, Bronchoalveolar lavage and Immune protection. Her Immune system research incorporates themes from Antibody, Viral vector and Antigen.
Helen McShane mostly deals with Tuberculosis, Vaccination, Immunology, Intensive care medicine and Mycobacterium tuberculosis. The Vaccination study which covers Immune system that intersects with Viral vector, Virology and Pulmonary tb. Her Immunology study combines topics in areas such as Regimen and Adverse effect.
Her Intensive care medicine research is multidisciplinary, incorporating perspectives in Tuberculosis vaccines, Clinical trial and Licensure. The study incorporates disciplines such as Causative organism and Immune mechanisms in addition to Tuberculosis vaccines. She has included themes like Lung, Antigen presentation, Parenchyma and Nasal administration in her Mycobacterium tuberculosis study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
Michele D Tameris;Mark Hatherill;Bernard S Landry;Thomas J Scriba.
The Lancet (2013)
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
Helen McShane;Ansar A Pathan;Clare R Sander;Sheila M Keating.
Nature Medicine (2004)
Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells.
Ajit Lalvani;Ansar A. Pathan;Helen McSHANE;Robert J. Wilkinson.
American Journal of Respiratory and Critical Care Medicine (2001)
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara
Nilu P. Goonetilleke;Helen McShane;Carolyn M. Hannan;Richard J. Anderson.
Journal of Immunology (2003)
Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment.
Ansar A. Pathan;Katalin A. Wilkinson;Paul Klenerman;Helen McShane.
Journal of Immunology (2001)
COVID-19 Vaccine Hesitancy in the UK: The Oxford Coronavirus Explanations, Attitudes, and Narratives Survey (OCEANS) II.
Daniel Freeman;Daniel Freeman;Bao S. Loe;Andrew Chadwick;Cristian Vaccari.
Psychological Medicine (2020)
Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.
Emily K. Forbes;Clare Sander;Edward O. Ronan;Helen McShane.
Journal of Immunology (2008)
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
Natalie E. R. Beveridge;David A. Price;David A. Price;Joseph P. Casazza;Ansar A. Pathan.
European Journal of Immunology (2007)
Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
Helen McShane;Helen McShane;Roger Brookes;Sarah C. Gilbert;Adrian V. S. Hill;Adrian V. S. Hill.
Infection and Immunity (2001)
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Matilu Mwau;Inese Cebere;Julian Sutton;Priscilla Chikoti.
Journal of General Virology (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: